Minimal residual disease (MRD) is being used more frequently in clinical trials and to identify the best treatment course for patients, but unknowns remain about the optimal use of MRD testing. While ...
MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...
Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual ...
Using tests to identify minimal residual disease may help determine how much treatment patients with multiple myeloma require. The landscape of multiple myeloma is changing, which is now bringing in ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients ...
Cost evaluation of adjunctive osimertinib use in resected epidermal growth factor receptor-positive non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results